European Neuropsychopharmacology最新文献

{"title":"Racial and ethnic diversity in zuranolone and brexanolone clinical trials for postpartum depression: A cross-sectional analysis of ClinicalTrials.gov","authors":"Damian Swieczkowski , Aleksander Kwaśny , Michal Pruc , Lukasz Szarpak , Wiesław Jerzy Cubała","doi":"10.1016/j.euroneuro.2025.03.005","DOIUrl":"10.1016/j.euroneuro.2025.03.005","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"96 ","pages":"Pages 5-6"},"PeriodicalIF":6.1,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143815307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting 10-year risk of chronic kidney disease in lithium-treated patients with bipolar disorder: A risk model development and internal cross-validation study","authors":"Joe Kwun Nam Chan ,&nbsp;Marco Solmi ,&nbsp;Christoph U Correll ,&nbsp;Corine Sau Man Wong ,&nbsp;Heidi Ka Ying Lo ,&nbsp;Francisco Tsz Tsun Lai ,&nbsp;Wing Chung Chang","doi":"10.1016/j.euroneuro.2025.03.008","DOIUrl":"10.1016/j.euroneuro.2025.03.008","url":null,"abstract":"<div><div>Lithium is a first-line maintenance treatment for bipolar-disorder (BD) but has increased risk for chronic-kidney-disease (CKD). There is a paucity of research on risk-model development predicting CKD during/following lithium treatment, and none was conducted in Asian regions. This study aimed to derive and validate 10-year risk prediction model for CKD-stage 3 in first-diagnosed BD patients receiving ≥ 1 prescription of lithium during 2002–2018 in Hong-Kong, using electronic-medical-record database of public-healthcare services. Literature-informed predictor selection included demographics, physical comorbidities, mean lithium serum-levels and non-lithium psychotropic use. The risk-equation was developed using Least-Absolute-Shrinkage-and-Selection-Operator (LASSO) Cox-proportional hazards regression model with 4-fold internal cross-validation over 1,000 iterations. We identified 2,258 lithium-treated BD patients, with CKD incidence of 12.6 per 1000 person-years (95 %CI=11.1–14.4) over a median follow-up of 7.7 years (interquartile range=3.7–12.3). Our results showed that older age at BD-diagnosis, male sex, physical comorbidities, higher mean lithium serum-level, fewer antipsychotic and mood-stabilizing anticonvulsant use, and greater antidepressant exposure were independent risk factors predicting CKD, with an event-per-variable ratio of 25.2. The 10-year risk prediction model had satisfactory area-under-the-curve (AUC) (0.74 [95 %CI=0.66–0.83]), with good calibration (calibration slope=0.88 [95 %CI=0.61–1.15]; observed/expected risk ratio=1.14 [95 %CI=0.86–1.42]), and discrimination performances (Harrell's C-index=0.75 [95 %CI=0.68–0.82]; Royston and Sauerbrei's D statistic=1.45 [95 %CI=0.99–1.92]). In conclusion, this CKD risk-model for lithium-treated BD patients demonstrated satisfactory prediction performance in a predominantly-Chinese population. Further research including external validation is needed to verify model performance to facilitate implementation of this CKD risk prediction tool for individualized clinical decision-making and outcomes in real-world practice.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Pages 24-30"},"PeriodicalIF":6.1,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Creatine as a treatment for depression: A brain bioenergetics perspective","authors":"Nicholas Fabiano ,&nbsp;Brendon Stubbs","doi":"10.1016/j.euroneuro.2025.03.014","DOIUrl":"10.1016/j.euroneuro.2025.03.014","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"96 ","pages":"Pages 3-4"},"PeriodicalIF":6.1,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143815306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on the Article “Optimizing differential diagnostics and identifying transdiagnostic treatment targets using virtual reality”","authors":"Sijia Liu ,&nbsp;Xicai Liang ,&nbsp;Juntong Liu","doi":"10.1016/j.euroneuro.2025.02.016","DOIUrl":"10.1016/j.euroneuro.2025.02.016","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Pages 31-32"},"PeriodicalIF":6.1,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking suicide prediction: From static risk factors to dynamic models","authors":"Aiste Lengvenyte ,&nbsp;Philippe Courtet","doi":"10.1016/j.euroneuro.2025.03.012","DOIUrl":"10.1016/j.euroneuro.2025.03.012","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"96 ","pages":"Pages 1-2"},"PeriodicalIF":6.1,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143815305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing PANSS-6 and PANSS-30 for clinical and functional outcomes in first-episode psychosis: A 2-year follow-up in a Spanish cohort","authors":"Vicent Llorca-Bofí ,&nbsp;Marina Garriga ,&nbsp;Gisela Mezquida ,&nbsp;Clemente Garcia-Rizo ,&nbsp;Eduard Vieta ,&nbsp;Covadonga M. Díaz-Caneja ,&nbsp;Miquel Bernardo ,&nbsp;Santiago Madero ,&nbsp;Laura Pina-Camacho ,&nbsp;Manuel J. Cuesta ,&nbsp;Daniel Bergé ,&nbsp;Inmaculada Baeza ,&nbsp;Miquel Bioque ,&nbsp;Silvia Amoretti","doi":"10.1016/j.euroneuro.2025.03.011","DOIUrl":"10.1016/j.euroneuro.2025.03.011","url":null,"abstract":"<div><div>Assessing clinical symptoms in First Episode Psychosis (FEP) is essential for guiding treatment decisions and predicting outcomes. The Positive and Negative Syndrome Scale (PANSS-30) is widely used for this purpose; however, its length limits feasibility in routine clinical practice. The PANSS-6, a shorter version, represents a promising alternative, though its performance in FEP populations remains underexplored. This study evaluated the predictive abilities of PANSS-30 and PANSS-6 for clinical remission, functional remission, and relapse over a 2-year follow-up in a Spanish cohort of 193 FEP patients. Data were derived from the PEPs Project, with PANSS-30 assessments conducted at baseline and at 2, 6, 12, and 24 months; PANSS-6 scores were calculated from PANSS-30 at the same visits. Clinical remission, functional remission, and relapse were defined using established criteria. Logistic regression and ROC-AUC analyses assessed predictive and discriminatory performance. Agreement between the Remission in Schizophrenia Working Group (RSWG) for PANSS-30 and PANSS-6 remission criteria was near-perfect at 1 and 2 years (κ ≥ 0.98). PANSS-6 demonstrated stronger predictive associations and similar discriminatory performance to PANSS-30 for clinical and functional remission, while its performance for relapse over two years was similar. In conclusion, the PANSS-6 is a reliable and efficient tool for assessing clinical outcomes in FEP, offering similar predictive accuracy to PANSS-30 while being more practical for routine use due to its shorter administration time.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Pages 9-13"},"PeriodicalIF":6.1,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Negative Symptoms in Schizophrenia: The Placebo Effect as a Barrier to Drug Development?","authors":"Istvan Bitter,&nbsp;Pal Czobor","doi":"10.1016/j.euroneuro.2025.03.006","DOIUrl":"10.1016/j.euroneuro.2025.03.006","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Pages 7-8"},"PeriodicalIF":6.1,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency, correlates and outcomes of Benzodiazepine use during Cariprazine treatment: A pooled post-hoc analysis from four 6-week, placebo-controlled trials in patients with an acute exacerbation of schizophrenia","authors":"Christoph U. Correll ,&nbsp;Réka Csehi ,&nbsp;Károly Acsai ,&nbsp;Ágota Barabássy","doi":"10.1016/j.euroneuro.2025.02.010","DOIUrl":"10.1016/j.euroneuro.2025.02.010","url":null,"abstract":"<div><div>Given the frequent prescription of benzodiazepines (BZDs) as adjunctive treatment to antipsychotics, this study aimed to uncover how BZD use affects treatment outcomes with cariprazine (CAR).</div><div>This post-hoc analysis used pooled data from four placebo-controlled trials in patients with acute schizophrenia. Efficacy evaluations involved changes from baseline to Week 6 on PANSS Total Score, Marder Positive Factor Score, Excitement Component Subscale Score, and Marder Anxiety Single Item Score. Safety evaluations focused on extrapyramidal symptoms and akathisia. Comparisons were made between CAR alone vs. placebo (PLB) alone; CAR+BZD vs. PLB+BZD; CAR alone vs. CAR+BZD; and PLB alone vs. PLB+BZD.</div><div>Data from 1643 patients were analysed (CAR only=943; CAR+BZD=132; PLB only=475; PLB+BZD=93). CAR alone yielded significantly greater improvement on all measures than PLB alone. CAR+BZD yielded significantly greater improvements in overall schizophrenia symptoms than PLB+BZD. CAR alone showed greater improvements in overall, positive, and anxiety symptoms compared to CAR+BZD. PLB alone yielded significantly greater improvements in positive and anxiety symptoms than PLB+BZD. Anxiety and agitation were the leading reasons for BZD administration. CAR was associated with more akathisia and EPS in both the non-BZD and BZD-user groups than PLB.</div><div>The results support the superior efficacy of CAR with or without BZD co-treatment for total and positive symptoms of schizophrenia compared to PLB with or without BZD use. These findings suggest BZDs should be used for emergent symptoms like anxiety or agitation, rather than core schizophrenia symptoms.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 76-83"},"PeriodicalIF":6.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: Premature conclusions on antipsychotic continuation in environmentally conscious psychopharmacotherapy","authors":"Matthias Brunn ,&nbsp;Fabrice Berna","doi":"10.1016/j.euroneuro.2025.03.002","DOIUrl":"10.1016/j.euroneuro.2025.03.002","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Page 6"},"PeriodicalIF":6.1,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143610331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicles in mood disorders: A systematic review of human studies","authors":"Cristian-Daniel Llach ,&nbsp;Gia Han Le ,&nbsp;Sebastian Badulescu ,&nbsp;Gerard Anmella ,&nbsp;Hayder Ali Hasan ,&nbsp;Anna Giménez-Palomo ,&nbsp;Isabella Pacchiarotti ,&nbsp;Eduard Vieta ,&nbsp;Roger S. McIntyre ,&nbsp;Joshua D. Rosenblat ,&nbsp;Rodrigo B. Mansur","doi":"10.1016/j.euroneuro.2025.02.009","DOIUrl":"10.1016/j.euroneuro.2025.02.009","url":null,"abstract":"<div><div>Extracellular vesicles (EVs) are small, membrane-bound particles that are naturally released by nearly all cell types in the body. They serve as molecular biosignatures, reflecting the state of their cells of origin and providing a non-invasive peripheral marker of central nervous system (CNS) activity under physiological and pathological conditions. We conducted a systematic review (ID: CRD42024528824) of studies investigating the use of EVs in mood disorders within clinical populations. We screened articles indexed in PubMed, EMBASE, Scopus, ISI Web of Science, and APA PsycInfo from January 2010 to October 2024. Available research has focused on four key areas: (1) EV cargo as mechanistic and diagnostic biomarkers; (2) EV cargo as predictive or tracking biomarkers for antidepressant response; (3) EV cargo and neuroimaging correlates; and (4) EV physical properties. Most studies examined major depressive disorder (MDD), with others addressing bipolar disorder (BD), adolescent depression, postpartum depression, and late-life depression. Notably, only 35,55 % of the studies utilized brain-derived EVs. Through analyses of EV-derived miRNA, proteins, mtDNA, and metabolites, these studies have explored neural mitochondrial function, brain insulin resistance, neurogenesis, neuroinflammation, and blood-brain barrier permeability in the context of mood disorders. Some EV-derived markers demonstrated diagnostic and predictive potential. This review discusses key findings, limitations of current research, and future directions for leveraging EVs in the study of mood disorders.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 59-75"},"PeriodicalIF":6.1,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}